Start Β· Catalogue Β· Profile Β· Table
Screening BODY HANDBOOK
Screening Β· Β§139
RSV Vaccine for Adults
The RSV vaccine cuts your odds of being hospitalized for RSV by about three-quarters β€” and adult RSV puts somewhere between 60,000 and 160,000 Americans in the hospital every winter, most of them over 75. It's a single shot, once in a lifetime, and for nearly everyone on Medicare or a typical insurance plan it's free. The catch is who qualifies: the rules are age- and risk-stratified, and not every adult should get it. What follows is who's eligible right now, what the trials actually show, what the shot costs you in side effects, and how to fit it alongside the rest of your fall vaccines.
Decide Β· Once Evidence Moderate Chapter Screening

If you're 75 or older, the call is simple: one shot, this fall, before RSV season starts. Roughly three of every four RSV hospitalizations are prevented in the first year after vaccination, and most of that protection carries into year two. If you're 50 to 74, eligibility depends on whether you have a chronic heart or lung condition, diabetes with complications, severe obesity, weakened immunity, or a few related risks β€” a short conversation with your doctor or pharmacist sorts it out. The price you pay is a sore arm and maybe a day of feeling tired; the price tag is usually zero.

The shot teaches your immune system to recognize one specific shape on RSV's surface β€” the version of the virus's spike that it uses to fuse with and break into your lung cells. That shape is fragile and hard to put inside a vaccine; a 2013 structural-biology breakthrough finally pinned it down, and that's what made the current generation of RSV vaccines possible.

Three products are FDA-approved for adults. Arexvy (GSK) is a piece of the protein paired with an adjuvant β€” the same adjuvant family used in the Shingrix shingles shot β€” which helps older immune systems mount a stronger response. Abrysvo (Pfizer) is a similar protein piece, no adjuvant, with both major RSV strains covered. mResvia (Moderna) is an mRNA shot, from the same platform family as the COVID mRNA vaccines but carrying instructions for the RSV spike instead. All three raise virus-neutralizing antibodies roughly ten- to fifteen-fold from baseline, and most of your protection is on board within two to four weeks Papi 2023Walsh 2023Wilson 2023.

What the trials and the hospital data actually show

Three large randomized trials, each enrolling between 25,000 and 37,000 adults aged 60 and up, found the shot prevented somewhere between roughly two-thirds and over four-fifths of RSV-caused lower respiratory illness in the first season after vaccination. Protection against the most severe outcomes β€” ICU admission, death β€” ran even higher.

The real test isn't the trial; it's whether the shot stops people from showing up at the hospital in the actual world. CDC surveillance networks tracking real hospitalizations across the 2023-2024 season landed close to the trial numbers: in adults 60 and older, the vaccinated were about 75-80% less likely to be hospitalized for RSV than the unvaccinated, and the gap was wider still for the worst outcomes Surie 2024.

Year two is where the picture gets a little messier. Protection against milder illness fades β€” the two-season Arexvy data settles around two-thirds β€” but protection against severe disease and hospitalization holds up better. Whether and when a booster will be added is being studied; for now, current guidance is a single lifetime dose.

Who's eligible right now

The current CDC rules (updated in 2024) sort adults into three buckets Britton 2024:

  • 75 and older β€” recommended for everyone in this group, regardless of how healthy you are. One shot.
  • 60 to 74 β€” recommended if you have any of the risk conditions below. Otherwise, not routinely recommended.
  • 50 to 59 β€” recommended under newer 2024-2025 guidance if you have any of the risk conditions below.

The risk conditions that move you into the recommended group:

  • Chronic heart disease β€” heart failure, coronary artery disease
  • Chronic lung disease β€” COPD, asthma, scarring lung disease
  • Diabetes with complications affecting your kidneys, eyes, or nerves
  • Serious kidney or liver disease
  • Severe obesity (a BMI of 40 or higher)
  • A weakened immune system β€” from HIV, an organ transplant, certain cancers, or medications that suppress immunity (including some biologics)
  • Blood disorders such as sickle cell disease
  • Neurologic conditions that interfere with coughing or swallowing
  • Living in a nursing home or long-term care facility
  • Frailty in general

If you're under 60 and don't have any of these, the shot isn't currently recommended for you. The exception is pregnancy, which is a separate decision with a different product and timing β€” see the closing pointers below.

When and how to get it

Time it for late summer or early fall β€” August through October works in most of the US β€” so your peak protection lines up with RSV season, which usually runs November through March. The shot goes in your upper arm, one dose, and you're covered within two to four weeks.

One practical note: pharmacies (CVS, Walgreens, Walmart, Costco) are usually faster than a primary-care appointment for this. Most US states let pharmacists administer adult vaccines without a prescription under standing orders, and walk-ins are common.

Side effects and the safety signal worth knowing about

For most people, the cost is 24 to 48 hours of a sore arm and maybe a stretch of feeling tired, achy, or mildly feverish β€” the same kind of reaction Shingrix produces. A small share have stronger reactions; almost no one has a reaction that lasts beyond a couple of days.

The one signal that deserves a straight conversation with your doctor is Guillain-BarrΓ© syndrome β€” a rare nerve illness in which your immune system briefly attacks the lining of your nerves. In the trials and in early Medicare data, RSV-vaccinated adults had about seven to nine extra cases of Guillain-BarrΓ© per million doses. That's roughly one extra case per 100,000 to 150,000 people vaccinated. The CDC reviewed the signal in 2024 and kept the recommendation in place because the same population avoids many more hospitalizations and several extra deaths from RSV per 100,000 vaccinated Britton 2024. The math favors the shot β€” but you should know the signal is there.

A separate early signal of irregular heartbeats from one of the trials has not been borne out in real-world data so far.

Cost and where to get it

For nearly everyone in the US who's eligible, the shot is free at the counter. Since January 2023, Medicare Part D covers all CDC-recommended adult vaccines with no copay, no deductible, and no coinsurance β€” a change made by the Inflation Reduction Act. Most private insurance plans (the ones that comply with the ACA) cover it the same way, as a preventive service with no cost-sharing. Without insurance, the cash price runs about $280 to $320.

Any major pharmacy chain stocks it. You don't need a prescription in most states; you can walk in. Bring your insurance card and your usual ID. If you have Medicare, make sure your Part D plan is processing the claim, not Part B β€” pharmacies handle this correctly almost always, but it's worth asking if the counter quotes you a price.

What you're betting against

The 80-year-old who skips the shot doesn't notice anything in most years. Then comes the November where a cough that should have cleared in a week is still there in two, and the breathing gets worse on the way to the bathroom, and a daughter convinces them to go to urgent care, and urgent care sends them on to the hospital. The five-day stay is the part everyone braces for. The part that catches families off guard is the months after β€” the slower walk to the mailbox, the unsteady stair, the grandchildren visit where everyone notices Grandma isn't quite back. A meaningful share of older adults hospitalized with a serious respiratory illness don't return to their old baseline. The hospital trip ends; the version of them that lived independently before doesn't always come back the same.

RSV in adults isn't a children's disease that you happen to catch β€” it's its own thing. In a typical US year, it puts somewhere between 60,000 and 160,000 adults aged 60 and older in the hospital, and it kills between 6,000 and 10,000 of them Hansen 2022. In any single winter the odds for one individual are small. The decade adds up.

What most people get wrong

  • "RSV is something kids get." True for kids and true for adults β€” for adults over 60, it's a top cause of winter hospitalization, on the same order as flu in some seasons.
  • "I had RSV once, so I'm immune." No. Natural immunity wears off. Most adults catch RSV many times over a lifetime.
  • "I'll need a booster next year." Not currently. One dose, and that's the rule until the data on year three and beyond settle.
  • "I'm pregnant β€” I should get Arexvy." No. Only Abrysvo is approved for pregnancy, and only in a specific window. Arexvy and mResvia are not.
  • "Healthy 65-year-olds should get it." Under the 2024 update, the routine recommendation starts at 75. Healthy 60-to-74-year-olds aren't on the recommended list unless they have a qualifying condition β€” though some choose to get it after a conversation with their doctor.

Related decisions

  • Maternal RSV vaccination. Abrysvo given at 32 to 36 weeks of pregnancy in the fall and winter protects newborns through their first season β€” a separate decision with different timing.
  • Infant RSV protection. Babies in their first RSV season are protected by an antibody injection (nirsevimab), not a vaccine. Different product, different conversation.
  • The rest of the fall vaccine visit. Influenza, COVID-19, pneumococcal, shingles, and Tdap booster all stack on top of this one β€” and the easiest path is to do as many as possible in the same appointment.
Related in the handbook
Related
  • β€” The shingles shot belongs right next to this one if you're over 50 β€” same visit, both usually free.
  • β€” The RSV shot stacks neatly onto the rest of your fall vaccine visit β€” easiest to do them in one appointment.
  • β€” A chronic lung condition like COPD moves you into the eligible group at 50–74 β€” and makes RSV more dangerous if you catch it.
Β·
139